Immunovant, Inc. (IMVT) stock
IMVTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends March 31
$33.21−0.07 (-0.21%)
Close on Nov 17, 2026Market cap $6.86BP/E –Yield –
Immunovant ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
No ebitda figures for Immunovant
Immunovant has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.
See a number that looks wrong?